Rafael Simó
Barcelona, 08035, Spain
NCT Number: NCT04281186
The retina shares similar embryologic origin, anatomical features and physiological properties with the brain and hence offers a unique and accessible "window" to study the correlates and consequences of subclinical pathology in patients with cognitive impairment. Our hypothesis is that the neurodegeneration of the retina will run in parallel to the neurodegeneration of the brain and, therefore, the signs of neurodysfunction in the retinal assessment will be more evident in those patients with rapid cognitive decline. Microangiopathy will also participate in cognitive decline and its specific role, as well as usefulness of retinal imaging, will be also examined.
This is a multinational and multicentre cross-sectional study and prospective, longitudinal cohort observational study.
Looking for future studies?
Notify Me65 year and older
All sexes
Observational
Barcelona, 08035, Spain
The study consists of two main parts: a cross-sectional part and a longitudinal part, aimed at a) to determine whether functional and/or structural retinal biomarkers or circulating biomarkers are able to differentiate people with mild cognitive impairment (MCI) within the type 2 diabetes (T2D) population (the investigators will be able to do in the cross-sectional study, and, thus, use retina and/or blood biomarkers as a potential proxy to events taking place in the brain); b)to determine whether functional and/or structural retinal biomarkers or circulating biomarkers can be used to determine the speed of cognitive decline in people with T2D and MCI and those at higher risk of developing dementia.
The cross-sectional study will allow characterization of a large group of individuals with T2D (720 participants) and establish correlations between the various functional and structural retinal endpoints obtained and the presence/absence of mild cognitive impairment (MCI) and dementia. The cross-sectional study will allow identification of T2D patients with MCI; of these a group of 168 T2D patients with MCI and a group of T2D patients without MCI (n=63), which will act as a control group, will be then followed prospectively in the longitudinal cohort study to evaluate end points predictive of cognitive decline and dementia.
The primary objective is: to assess whether retinal sensitivity measured by microperimetry is able to predict cognitive decline and progression to dementia in MCI T2D patients.
The secondary objectives are:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Prospective study:
In addition to the above, participants enrolled in the prospective longitudinal cohort study should fulfilled the following criteria:
Exclusion criteria
Prospective study:
In addition to the above, participants enrolled in the prospective longitudinal cohort study should fulfilled the following criteria:
Time frame: 48 month
Assessed by microperimetry
Time frame: 48 month
Assessed by gaze fixation: areas BCEA63, BCEA95 and P1, P2 fixation points will be evaluated
Time frame: 48 month
Full-field photopic electroretinogram (ERG)
Time frame: 48 month
Spectral Domain Optical Coherence Tomography (SD-OCT): measurement of the retinal layers .
Time frame: 48 month
Assessed by Optical Coherence Tomography Angiography (OCT-A)
Time frame: 48 month
Ultra-wide field Fundus Fluorescein Angiography (FFA).
Time frame: 48 month
Assessed by Magnetic Resonance Imaging (MRI).
Time frame: 48 month
18 Fluoro-2-deoxyglucose-Positron Emission Tomography (18FDG-PET).
Time frame: 48 month
Blood samples: proteomics, complement system, inflammatory mediators, glial acidic fibrillary protein, HOMA-IR
Time frame: 48 month
Geriatric Depression Scale (GDS-15): scores 0-4 normal, 5-8 mild depression, 9-11 moderate depression, 12-15 severe depression
Time frame: 48 month
EQ-5D-3L questionnaire . The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
Time frame: 48 month
25-item National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) . The NEI VFQ-25 contains a reduced number of items within each subscale of the original 51-item NEI VFQ. 13,29 The 12 subscales in the NEI VFQ-25 are general vision, near vision, distance vision, driving, peripheral vision, color vision, ocular pain, general health, and vision-specific role difficulties, dependency, social function, and mental health. The subscale scores are calculated by summing the relevant items and transforming the raw scores into a 0 to 100 scale where higher scores indicate better functioning or well-being. The total score of the NEI VFQ-25 is an average of 11 subscale scores, excluding the single-item general health subscale.
Time frame: 48 month
Diabetes Specific Dementia Risk Score (DSDRS). Briefly,the score is based on the age of the patients, history of any acute metabolic decompensation, the presence micro and/or macrovascular complications of the diabetes, depression and education level, obtaining a score ranged between -1 and 19. The higher the score, more risk of developing dementia at 10 years follow-up.
Hospital Universitari Vall d'Hebron Research Institute
Other
Retinal and Cognitive Dysfunction in Type 2 Diabetes: Unraveling the Common Pathways and Identification of Patients at Risk of Dementia
Acronym: RECOGNISED
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01269151
Age-Related Macular Degeneration, Eye Diseases
Lübeck, Germany
View Trial DetailsNCT05504811
Brain Diseases, Central Nervous System Diseases
Downey, California, United States
View Trial DetailsNCT06977815
Aging, Cognition Disorders
Badalona, Barcelona, Spain
View Trial DetailsNCT07690553
Behavior, Behavioral Symptoms
Wuhan, Hubei, China
View Trial Details